Netobill Pharma Limited
Founded in 2019 and headquartered in Uttarakhand, India.
2019 | Haridwar, Uttarakhand (India) | Active
Netobill Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 5 Year, 8 Months
About Netobill Pharma
Netobill Pharma Limited (NPL) is a Public Limited Indian Non-Government Company incorporated in India on 17 June 2019 (Five years and eight months 12 days old ). Its registered office is in Haridwar, Uttarakhand, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Phool Chandra, Pradeep Maurya, Ram Nath, and Two other members serve as directors at the Company.
Company Details
- Location
Haridwar, Uttarakhand, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239UR2019PLC009911
- Company No.
009911
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
17 Jun 2019
- Date of AGM
-
- Date of Balance Sheet
-
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Chemicals
Pharmaceuticals
Who are the key members and board of directors at Netobill Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradeep Maurya  | Managing Director | 17-Jun-2019 | Current |
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Phool Chandra | Director | 17-Jun-2019 | Current |
| Ram Nath | Director | 16-Mar-2023 | Current |
| Sanjay Kumar | Director | 16-Mar-2023 | Current |
| Chandrakant Maurya | Director | 17-Jun-2019 | Current |
Financial Performance of Netobill Pharma.
Enhance accessibility to Netobill Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Netobill Pharma?
Unlock access to Netobill Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Netobill Pharma?
Unlock and access historical data on people associated with Netobill Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Netobill Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Netobill Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.